Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Net Income (2016 - 2025)

Heron Therapeutics' Net Income history spans 14 years, with the latest figure at $38000.0 for Q4 2025.

  • For Q4 2025, Net Income fell 99.09% year-over-year to $38000.0; the TTM value through Dec 2025 reached -$2.5 million, up 77.98%, while the annual FY2025 figure was -$10.2 million, 27.23% up from the prior year.
  • Net Income reached $38000.0 in Q4 2025 per HRTX's latest filing, up from -$4.1 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $4.2 million in Q4 2024 to a low of -$62.9 million in Q1 2022.
  • Average Net Income over 5 years is -$25.9 million, with a median of -$22.6 million recorded in 2022.
  • The largest YoY upside for Net Income was 165.74% in 2025 against a maximum downside of 99.09% in 2025.
  • A 5-year view of Net Income shows it stood at -$53.5 million in 2021, then soared by 61.98% to -$20.4 million in 2022, then skyrocketed by 49.79% to -$10.2 million in 2023, then surged by 140.83% to $4.2 million in 2024, then crashed by 99.09% to $38000.0 in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Net Income are $38000.0 (Q4 2025), -$4.1 million (Q3 2025), and -$1.6 million (Q2 2025).